Theralase adds omitted Adstiladrin safety, prescribing details in corrected Q2 2026 release
Theralase issued a corrected replacement of its Q2 2026 financial statements, adding omitted safety and prescribing information for Adstiladrin. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information,